Many patients with gastro-oesophageal reflux disease (GERD) continue to experience troublesome symptoms such as heartburn and acid regurgitation despite proton pump inhibitor (PPI) therapy. The new-generation PPI dexlansoprazole, developed with a dual delayed-release (DDR) technology, fills this treatment gap. At a symposium during the Asia-Pacific Digestive Week 2016 in Kobe, Japan, experts discussed the use of PPIs for prevention of antiplatelet drug-associated gastroduodenal injury and GERD management guidelines.
Proton pump inhibitors (PPIs) have revolutionized the treatment of gastro-oesophageal reflux disease (GERD). Despite their efficacy, many patients continue to show a suboptimal response to long-term treatment with conventional PPIs. At a symposium during the 24th United European Gastroenterology Week in Vienna, Austria, experts discussed challenges in the evaluation and management of GERD and the role of dexlansoprazole in GERD treatment.
Angiogenesis inhibition by anti-VEGF agents is widely used in the treatment of metastatic colorectal cancer (mCRC) and other cancer types, but resistance to antiangiogenic treatment presents a clinical challenge. At the European Society for Medical Oncology (ESMO) Congress 2016 held recently in Copenhagen, Denmark, experts reviewed the mechanisms of resistance and discussed new approaches that address the resulting treatment gap, focusing on the benefits of aflibercept, a VEGF trap that effectively blocks multiple proangiogenic factors to disrupt tumour blood supply.
The prevalence of gastro-oesophageal reflux disease (GERD) in Hong Kong is showing an increasing trend. Despite long-term therapy with proton pump inhibitors (PPIs), many patients with GERD continue to experience symptoms that affect quality of life (QoL). According to Dr Victoria Tan of the Department of Medicine, The University of Hong Kong (HKU), GERD is emerging as a diagnostic and therapeutic challenge. Dexlansoprazole, a new-generation PPI with a dual delayed-release (DDR) system, addresses the limitations of conventional GERD treatment.